Fused cyclic compounds

A compound, benzene ring technology, applied in the digestive system, organic chemistry, drug combination, etc., can solve the problem of undisclosed compounds, etc., and achieve the effects of excellent stability, good pharmacokinetic properties, and excellent GPR40 receptor agonist activity

Active Publication Date: 2009-12-30
TAKEDA PHARMA CO LTD
View PDF14 Cites 42 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0025] However, none of the above-mentioned documents discloses the compound of the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fused cyclic compounds
  • Fused cyclic compounds
  • Fused cyclic compounds

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0353] The production method of compound (I) is explained below.

[0354] Unless otherwise stated, the individual symbols of the compounds in the following schemes are as defined above. Each compound in the scheme can form a salt as long as it does not inhibit the reaction. As such salts, those similar to the salts of compound (I) can be mentioned.

[0355] The compound obtained in each step can also be used in the next reaction as a crude product in the form of a reaction mixture, or can be separated from the reaction mixture according to a conventional method, and can be further easily purified by separation methods such as recrystallization, distillation, chromatography, etc. .

[0356] Compound (I) (for example, compounds represented by formulas (Ia) and (Ia') (abbreviated as compound (Ia) and compound (Ia', respectively))) can be obtained according to the method shown in Scheme 1 below or a similar method Prepare.

[0357] Diagram 1

[0358]

[0359] where R 1 ' ...

Embodiment

[0560] The present invention is further described in detail by the following reference examples, examples, formulation examples and experimental examples, which are merely examples, not intended to limit the present invention, and can be changed without departing from the scope of the present invention.

[0561] The term "room temperature" in the following Reference Examples and Examples means generally a range of about 10°C to about 35°C. The chemical yield (yield) is the isolated yield (mol / mol%) or the yield obtained by high performance liquid chromatography. The optical purity (asymmetric yield) of the optically active form is calculated on the basis of enantiomeric excess (% e.e.). The enantiomeric excess is determined by the following formula:

[0562] Enantiomeric excess (%e.e.) = 100X[(R)-(S)] / [(R)+(S)] or

[0563] 100X[(S)-(R)] / [(R)+(S)]

[0564] where (R) and (S) are the areas of the individual enantiomers in HPLC.

[0565] Solvents used in chromatography are exp...

reference example 1

[0596] Reference Example 1 4-(4-bromo-3,5-dimethylphenoxy)tetrahydro-2H-thiopyran

[0597]

[0598]To 4-bromo-3,5-dimethylphenol (0.201g, 1.00mmol), tetrahydro-2H-thiopyran-4-ol (0.130g, 1.10mmol) and triphenylphosphine (0.341g, 1.30mmol ) in tetrahydrofuran (5 mL) was added diethyl azodicarboxylate (40% solution in toluene, 0.591 mL, 1.30 mmol), and the mixture was stirred at room temperature for 1.5 hours. Add tetrahydro-2H-thiopyran-4-ol (0.0591 g, 0.500 mmol), triphenylphosphine (0.157 g, 0.600 mmol) and diethyl azodicarboxylate (40% solution in toluene, 0.272 mL , 0.600 mmol), the mixture was further stirred for 1.5 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=0:100-20:80) to obtain the title compound (0.261 g, yield 86%) as colorless crystals.

[0599] 1 H NMR (CDCl 3 )δ: 1.93-2.07 (2H, m), 2.10-2.23 (2H, m), 2.37 (6H, s), 2.49-2.61 (2H, m), 2.85-2.98 (2H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

Description

technical field [0001] The present invention relates to a novel condensed ring compound with function regulating function of GPR40 receptor. Background of the invention [0002] The following compounds have been reported as GPR40 receptor agonists useful as drugs for the prevention or treatment of diabetes and the like. [0003] (1) WO2004 / 041266 discloses a GPR40 receptor function modulator comprising a compound having an aromatic ring and a group capable of releasing cations. [0004] (2) WO2004 / 106276 discloses a compound represented by formula (I): [0005] [0006] in [0007] Ar is an optionally substituted cyclic group; [0008] Ring A is an optionally substituted ring (the ring should not be thiazole, oxazole, imidazole and pyrazole); [0009] Xa and Xb are each a bond or a spacer having 1-5 atoms in the main chain; [0010] Xc is O, S, SO or SO 2 ; [0011] yes or [0012] Ring B is a 5-7 member ring; [0013] Xd is a bond, CH or CH 2 ;and [001...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D409/12A61P3/10A61K31/192
CPCC07D409/12C07D307/80A61P1/04A61P1/14A61P13/12A61P15/00A61P17/00A61P19/02A61P19/08A61P25/00A61P25/18A61P25/24A61P25/28A61P27/02A61P29/00A61P3/00A61P3/04A61P31/10A61P35/00A61P3/06A61P37/02A61P37/08A61P43/00A61P5/50A61P7/02A61P7/10A61P9/10A61P9/12A61P3/10A61K31/192
Inventor 安间常雄根来伸行山下真之伊东昌宏
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products